CSV October 24, 2023 through October 24, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMIODARONE	CHEMICAL	*USP42–NF37*	253	27-Sep-2019	1-Oct-2019	*NA*	*NA*	See

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	INFORMATION							https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/september -2019-errata- with-image.pdf for correction.
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change *Diluent*, *Solution A*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*. to: *Diluent*, *Buffer solution*, *Solution A*, *Solution B*, *Mobile phase*, *System suitability solution*, *Chromatographic system*, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution: Proceed as directed in the *Assay*.
OLMESARTAN MEDOXOMIL TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official March 19, 2019)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In the *Analysis*: Change C_S = concentration of in the *Standard solution* (mg/mL) to: C_S = concentration of USP Olmesartan Medoxomil RS in the *Standard solution* (mg/mL)
PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	19. MEAN KINETIC TEMPERATURE	*USP42–NF37*	7831	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In *19.4 Example Calculations of MKT for CRT Storage Evaluation/Example 3—Calculation of Annual MKTStep 3*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3.354 to: 3.340 AND In *Step 4*: Change 2.795 to: 2.783 AND In *Step 5*: Change ?33.511 to: ?33.515 AND In *Step 6*: Change 298.410 to: 298.372
SILDENAFIL CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4002	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Sildenafil Related Compound A RS: Change 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpro

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one. $C_{23}H_{32}N_6O_4S$ 488.60 to: 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one; Also known as 1-{[3-(6,7-Dihydro-1-methyl-7-ox o-3-isobutyl-1*H*-pyraz

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								olo[4,3-*d*]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl}-4-methylpiperazine. $C_{23}H_{32}N_6O_4S$ 488.61
LEVOFLOXACIN	CHEMICAL INFORMATION	*USP42–NF37*	2552	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change Anhydrous [100986-85-41]. to: Anhydrous [100986-85-4].
MECLOFENAMATE SODIUM	CHEMICAL INFORMATION	*USP42–NF37*	2706	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W.
FEXOFENADINE HYDROCHL	ADDITIONAL REQUIREMENT	*Revision Bulletin (Official*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	S/*USP Reference Standards <11>*	*August 01, 2018)*						Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
FEXOFENADINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								enylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
FEXOFENADINE HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1830	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 538.12

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 499.65
FEXOFENADINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1828	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-y

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
CIDOFOVIR INJECTION	IM PURITIES/*Organic Impurities*	*USP42–NF37*	981	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In *Table 1*: Change 0.56 to: 0.59
CHLOROQUINE PHOSPHATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	939	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Chloroquine Related Compound G RS: Change $C_{18}H_{26}Cl_3NO \cdot H_2SO_4$ to: $C_{18}H_{26}ClN_3O \cdot H_2SO_4$
CALCIUM CARBONATE	IM PURITIES/*Limit of Magnesium and Alkali Salts*	*USP42–NF37*	666	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change *Sample solution*: 1.0 g to: *Sample*: 1.0 g
G49	CHROMATOG	*First*	8127	28-Jul-2019	20-Apr-2019	*USP42–NF37*	*First*	Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	RAPHIC CO LUMN S/*Packings*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	G49—Dimethylpolysiloxane with chiral building block containing D- or L-valine as chiral agent (for amino acids).
OXALIPLATIN INJECTION	IM PURITIES/*Limit of Oxalic Acid/ Chromatographic system*	*First Supplement to USP42–NF37*	8781	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Column*: Change L31 to: L81
ALPROSTADIL	ASSAY/ *Procedure*	*USP42–NF37*	151	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *System suitability stock solution*: Change *Standard solution* to: *Standard stock solution*
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION	SPECIFIC TESTS/ *Microbial Enumeration Tests <61> and Tests for Specified Microorganisms*	*USP42–NF37*	170	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change cfu/g to: cfu/mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	<62>							
BUSPIRONE HYDROCHLORIDE	IDENTIFICATION/*B.*	*USP42–NF37*	618	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change relative retention time to: retention time
BUSPIRONE HYDROCHLORIDE TABLETS	IDENTIFICATION/*B.*	*USP42–NF37*	621	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change relative retention time to: retention time
CHLOROTHIAZIDE	*Selenium <291>*	*USP42–NF37*	942	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change 0.003%. to: NMT 0.003%.
IOVERSOL	CHEMICAL INFORMATION	*USP42–NF37*	2345	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change *N*,*N*?-Bis(2,3-dihydroxypropyl)-5-*N*-(2-hydroxyethyl)glycol amido]-2,4,6-triiodoisophthalamide. to: *N*,*N*’-Bis(2,3-dihydroxypropyl)-5-[*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-(2-hydroxyethyl)glycolamido]-2,4,6-triiodoisophthalamide.
VALGANCICLOVIR HYDROCHLORIDE	*Related compounds*	*USP42–NF37*	4528	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In Column 2 of *Table 3*: Change Bis-valine easter of ganciclovir to: Bis-valine ester of ganciclovir
POWDERED MILK THISTLE EXTRACT	COMPOSITION */Content of Silymarin*	*USP42–NF37*	5102	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Table 2*: Change Tsosilybin B to: Isosilybin B
BENAZEPRIL HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*First Supplement to USP42–NF37*	8644	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In the *Standard solution*: Change µg/mL to: µg/µL
EPHEDRINE HYDROCHLORIDE	CHEMICAL INFORMATION	*First Supplement to USP42–NF37*	8682	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Add (1*R*,2*S*)-2-(Methylamino)-1-phenylpropan-1-ol hydrochloride;
LAMOTRIGINE	PERFORMANC	*First*	8720	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Buffer*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS FOR ORAL SUSPENSION	E TESTS/ *Dissolution <711>*/ *Chromatographic procedure 1*	*Supplement to USP42–NF37*						Change glacial acetic acid acid to: glacial acetic acid
LOVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	8727	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Mobile phase*: Change Processed as directed in the *Assay* to: Proceed as directed in the *Assay*.
BALANCES	REPEATABILITY	*First Supplement to USP42–NF37*	9011	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In all instances in paragraph 2: Change s_r to: s AND In paragraph 2: Change is found to be 0.0015, then M_{min} must be ? 0.3000 g or 300 mg. to: is found to be

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.00015, then M_{min} must be ? 0.30000 g or 300.00 mg.
TIAGABINE HY DROCHLORID E	ASSAY/ *Procedure*	*First Supplement to USP42–NF37*	8823	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times$?$(M_{r1}/M_{r2}) \times$? (USP 1-Aug-2019) 100 to: Result = $(R_U/R_S) \times (C_S/C_U) \times 100$ AND Delete ?M_{r1} = molecular weight of tiagabine hydrochloride, 412.00 M_{r2} = molecular weight of tiagabine hydrochloride monohydrate, 430.02? (USP 1-Aug-2019)
TIAGABINE HY IM		*First*	8823	26-Jul-2019	1-Aug-2019	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORIDE	PURITIES/*Limit of (S)-(+) Isomer*/*Mobile phase*	*Supplement to USP42–NF37*						Hexane, to: *n*-Hexane, AND Change hexane to: *n*-hexane
GLUCAGON BIOIDENTITY TESTS	*B. In Vitro Cell-Based Bioidentity Test*	*USP42–NF37*	6478	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Standard stock solution*: Change 0.4 µg/mL to: 4 µg/mL
POLYVINYL ALCOHOL	IDENTIFICATION	*USP42–NF37*	3566	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *B*: Change It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, and *Viscosity—Rolling Ball Method <913>*. to: It meets the requirements in the test

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Viscosity—Capillary Methods <911>, *Viscosity—Rotational Methods <912>*, or *Viscosity—Rolling Ball Method <913>*.
ETIDRONATE DISODIUM	SPECIFIC TESTS/*Water Determination <921>*	*USP42–NF37*	1745	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Sample solution*: Change acetic acid to: glacial acetic acid
SODIUM BICARBONATE	IM PURITIES/ *Carbonate*	*USP42–NF37*	4019	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate
VORICONAZOLE	IM PURITIES/ *Voriconazole*	*USP42–NF37*	4601	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Related Compounds C and D							0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in *Mobile phase*
ZONISAMIDE	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	4675	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change C_U = concentration of zonisamide related compound A in the *Sample solution* (mg/mL) to: C_U = concentration of zonisamide in the *Sample solution* (mg/mL)
CHOLINE BITARTRATE	IM PURITIES/*Limit of Total Amines*/*System*	*USP42–NF37*	4839	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	suitability							to: ?g/mL.
SAW PALMETTO EXTRACT	COMPOSITION /*Content of Long-Chain Alcohols and Sterols*	*USP42–NF37*	5196	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform
SAW PALMETTO CAPSULES	IDENTIFICATION/*B. Presence of Sterols*	*USP42–NF37*	5198	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sitosterol RS, and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform
CHITOSAN	ASSAY/*Degree of Deacetylation*	*USP42–NF37*	5663	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the *Analysis*: Change Result = {1 ? [(7 × A_2)/(3 × A_1)] × 100 to: Result = {1 ? [(7 × A_2)/(3 × A_1)]} × 100
ACETAMINOPHEN ORAL SUSPENSION	ASSAY	*Second Supplement to USP41–NF36*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the first *Procedure*: Change ?(Postponed on 1-Aug-2018) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official November 01, 2018)*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	?(RB 1-Aug-2018) In *Test 1*/*Tolerances* and *Test 3*/*Tolerances*: Change $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O)]$ to: $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$
CHOLINE CHLORIDE	IM PURITIES/*Limit of Total Amines*/*System suitability*	*USP42–NF37*	4841	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L. to: ?g/mL.
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*/*Analysis*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the *Standard solution* (mg/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the *Standard solution* (mg/mL)
GUANABENZ ACETATE	IM PURITIES/*Limit of 2,6-Dichlorobenzaldehyde/ Chromatographic system*	*USP42–NF37*	2129	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Column*: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm;
DOXORUBICIN HYDROCHLORIDE	ASSAY/ *Procedure*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	USP Doxorubicin Hydrochloride RS (µg/mg) In the fourth equation in *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Test 3*/*Procedure*: Change 1 N sodium hydroxide VS. to: 0.1 N hydrochloric acid VS.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DULOXETINE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In footnote a: Change This is a process impurity that is included in *Table 1* for identification purposes only. to: This is a process impurity that is included for identification purposes only.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19

- …
- Next page Next ›
- Last page Last »